tiprankstipranks
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H (GZPHF)
OTHER OTC:GZPHF
US Market

Guangzhou Baiyunshan Pharmaceutical Holdings Company (GZPHF) Financial Statements

Compare
3 Followers

Guangzhou Baiyunshan Pharmaceutical Holdings Company Financial Overview

Guangzhou Baiyunshan Pharmaceutical Holdings Company's market cap is currently $5.72B. The company's EPS TTM is $0.292; its P/E ratio is 8.03; and it has a dividend yield of 6.89%. Guangzhou Baiyunshan Pharmaceutical Holdings Company is scheduled to report earnings on March 17, 2025, and the estimated EPS forecast is $0.04. See an overview of income statement, balance sheet, and cash flow financials.
Dec 23Dec 22Dec 21Dec 20Dec 19
Income Statement
Total Revenue¥ 75.52B¥ 70.79B¥ 69.01B¥ 61.67B¥ 64.95B
Gross Profit¥ 14.19B¥ 13.28B¥ 13.23B¥ 10.44B¥ 12.87B
Operating Income¥ 5.12B¥ 5.07B¥ 4.79B¥ 3.67B¥ 4.06B
EBITDA¥ 6.49B¥ 5.00B¥ 5.82B¥ 4.68B¥ 3.90B
Net Income¥ 4.06B¥ 3.97B¥ 3.72B¥ 2.92B¥ 3.19B
Balance Sheet
Cash & Short-Term Investments¥ 21.31B¥ 22.56B¥ 22.38B¥ 19.47B¥ 18.47B
Total Assets¥ 78.59B¥ 74.67B¥ 66.12B¥ 59.76B¥ 56.89B
Total Debt¥ 11.70B¥ 11.43B¥ 9.92B¥ 9.56B¥ 6.65B
Net Debt¥ -9.61B¥ -11.07B¥ -12.45B¥ -9.91B¥ -11.82B
Total Liabilities¥ 41.91B¥ 41.03B¥ 34.79B¥ 31.55B¥ 30.90B
Stockholders' Equity¥ 34.92B¥ 32.07B¥ 29.06B¥ 26.14B¥ 24.18B
Cash Flow
Free Cash Flow¥ 2.48B¥ 5.62B¥ 4.42B-¥ 2.62B
Operating Cash Flow¥ 4.10B¥ 7.00B¥ 5.67B¥ 585.19M¥ 5.02B
Investing Cash Flow¥ -3.11B----
Financing Cash Flow¥ -1.98B¥ 45.95M-¥ 1.44B¥ -2.23B
Currency in CNY

Guangzhou Baiyunshan Pharmaceutical Holdings Company Earnings and Revenue History

Guangzhou Baiyunshan Pharmaceutical Holdings Company Debt to Assets

Guangzhou Baiyunshan Pharmaceutical Holdings Company Cash Flow

Guangzhou Baiyunshan Pharmaceutical Holdings Company Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis